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Summary 
Using the murine colon adenocarcinoma C-26 cell line, engineered to release granulocyte colony- 
stimulating factor (G-CSF) (C-26/G-CSF), we studied the mechanisms responsible for inhibi- 
tion of tumor take in syngeneic animals and of regression of an established tumor in sublethally 
irradiated mice injected with these cells. Immunocytochemistry and in situ hybridization, per- 
formed to characterize tumor-infiltrating lenkocytes and their cytokine expression, respectively, 
indicated that polymorphonudear leukocytes (PMN) were the major cells responsible for inhibi- 
tion of tumor take and that they expressed mKNA for intedeukin lc~ (IL-lcz), IL-1/3, and tumor 
necrosis factor c~ (TNF-cz). Expression of interferon 3' (IFN-3') and of IL-4 was undetectable, 
consistent  with the absence of T lymphocytes at the site of tumor injection. In mice injected 
with C-26/G-CSF cells after 600-tad irradiation, the tumors grew to "~1.5 cm in 30 d, regressing 
completely thereafter in 70-80% of mice. During the growing phase, tumors were infiltrated 
first by PMN (between days 15 and 20), then by macrophages, and last by T lymphocytes. Both 
CD4 + and CD8 + T cells were present but only CD8 depletion significantly abrogated tumor 
regression. Depletion of PMN by the RB6-8C5 antigranulocytes monoclonal antibody reduced 
the number of T cells infiltrating the tumor and prevented tumor regression. In situ hybridiza- 
tion performed at the beginning of tumor regression revealed the presence of mRNA for IL-la, 
IL-1/3, and TNF-ol, but also the presence of cells, with lymphoid morphology, expressing IFN-3'. 
Tumors from mice treated with recombinant IFN-3'  (between days 20 and 35) were rejected 
faster, whereas mice treated with antibodies to IFN-3' (from day 20) died of progressive tumor. 
Cydosporin A treatment (started at day 20) also abrogated tumor regression. These results indi- 
cate that inhibition of tumor take and regression in this model occurs through different mecha- 
nisms that involve PMN and PMN-T cell interactions,  respectively, as well as a combination 
of cytokines that, for tumor regression, require IFN-3'. Thus, gene transfer of a single cytokine 
gene such as G-CSF into tumor cells appears to be sufficient to trigger the cascade of cell interac- 
tions and cytokine production necessary to destroy  a cancer nodule. 
S 
tudies of peritumoral injection of lymphokine together 
with cytokine gene transfer into tumor cells show that 
local availability of cytokines exerts a potent antitumor ac- 
tivity without any apparent local or systemic  tc0ddty (reviewed 
in references 1 and 2). IL-2, -4, -6, -7, IFN-3', TNF-o~, and 
G-CSF  genes transfected  into tumor cells were shown to 
trigger different immune effector cells that eventually resulted 
in inhibition of tumor formation (2). However, all these studies 
were done using tumor cell suspension, and it is known that 
solid tumor fragments often grow progressively whereas even 
10-fold larger numbers of the identical tumor cell type in- 
jected as a suspension are rejected (3). Thus the tumor stroma, 
which consists of vessels, sessile, and migratory cells and ex- 
tracelhlar matrix, plays an important role in tumor growth 
and progression.  In addition, tumor cells modified to pro- 
duce cytokines are likely to have additional regulatory signals 
that result from cytokine-extracellular matrix crosstalk (4). 
Thus, the interaction of the tumor with host immune cells 
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of a tumor injected as a cell suspension might differ from 
those required to reject an established tumor nodule. Identi- 
fication and manipulation of the latter may, therefore, pro- 
vide a more direct approach to destroying solid tumors. 
In this report, we describe our analysis of the effector cells 
and the cytokines they produced during the rejection of a 
murine adenocarcinoma engineered to express G-CSF (5) and 
grown subcutaneously in a sublethally irradiated mice for 
30 d. The adenocarcinoma C-26/G-CSF does not grow in 
syngeneic mice when injected as a cell suspension containing 
>100-fold the number of C-26 cells required for minimal 
tumorigenic dose because of the PMN recruited and activated 
in situ by G-CSF released by tumor cells (5). In sublethally 
irradiated mice, C-26/G-CSF tumors grew progressively until 
the leukocyte count returned to  a  normal level  and then 
regressed in most of the mice (5). Here we show that inhibi- 
tion of tumor take and tumor regression occurs through 
different mechanisms, the former dominated by PMN, and 
the latter, by the cooperation of PMN with T cells, mediated 
by T  cell-derived IFN-3'. 
Materials  and Methods 
Tumors and Mice Studies.  C-26 is a murine colon adenocarci- 
noma cell line derived from BALB/c  mice treated with N-nitroso- 
N-methylurethane (6). Cells were maintained as tumors in vivo 
by subcutaneous transplant in syngeneic mice and adapted to cul- 
ture in DMEM (Gibco, Paisley,  UK) supplemented with 10% FCS 
(Gibe@ Construction of the NSV-G-CSF retroviral  vector, produc- 
tion of supernatant containing virus, infection of C-26 cells, and 
isolation clones producing G-CSF have  been described (5). Colony 
G4, which produces 90 pg/ml G-CSF/106 cells per 48 h, was used 
(5). BALB/c Ch mice were purchased from Charles River (Calco, 
Italy) and maintained at the Istituto Nazionale Turnoff  under stan- 
dard conditions according to institutional guidelines.  Tumorigenic 
activity of control and virus-infected  C-26 cells  was assayed  in mice 
injected subcutaneously in the right flank with cells in 0.2 ml of 
HBSS. Although a minimal dose of 3  x  104 C-26 cells/mouse  was 
required to induce tumors in 100% of injected mice, 104 cells were 
used in the present experiments. In some experiments mice were 
injected with tumor cells 24 h after sublethal whole body irradia- 
tion using a +~  source (,~4,000 Ci =  148,000 GBq; Theratron 
780C; Atomic Energy of Canada Limited, Kanata, Canada) to de- 
liver a dose rate of 28 rad/min for a total dose of 600 rad. On day 
20 after irradiation some mice were injected intraperitoneally with 
0.2 ml of HBSS containing 100/~g of anti-CD8 (53.6.72 hybridoma, 
Lyt2), anti-CD4 (GK1.5 hybridoma, L3T4), or anti-Mac-1 (M1/ 
70.15.11.5.HL hybridoma), all obtained from American Type Cul- 
ture Collection (ATCC; Rockville, MD), antigranulocyte (RB6- 
8C5 hybridoma; kindly provided  by Dr. Robert Coffman, DNAX, 
Palo Alto, CA), or anti-IFN-'y (AN18 hybridoma; kindly provided 
by Dr. G. Garotta, Roche, Basel). From days  20 to 35 after irradia- 
tion other  mice were injected intraperitoneally with 2  x  104 
U/mouse of mouse rIFN-3, (courtesy of Dr. G. Garotta) each day. 
In assays  to test the effect of cyclosporin  A on tumors, mice were 
injected  with this drug at a dose  of  75 mg/Kg (Sandimmun;  Sandoz, 
Basel, Switzerland) every 3 d from days 20 to 56 after irradiation. 
Leukocyte counts and blood composition were automatically de- 
termined using an H1 apparatus (Technicon  Chemicals Company, 
Tourney, Bdgium). 
MorphologicalAnalysis.  In nonirradiated  mice  injected  subcutane- 
ously with 104 C-26 or C-26/G-CSF cells, at least two mice from 
each group were killed at 24 h and at 5 d after injection. In irradi- 
ated mice injected with 106 C-26/G-CSF cells, at least two mice 
from each group were killed after 15 d and then every 2-3 d, until 
full rejection was established. The flanks were gently dissected and 
the tumor mass was recorded. Tumor fragments  and draining lymph 
nodes were embedded in OCT compound (Miles Lab., Elkhart, 
IN),  snap-frozen in liquid nitrogen,  and stored at  -80~ 
Iramunocytochemistr2/.  5-#m cryostat sections were fixed in ace- 
tone and immunostained with rat anti-mouse mAbs against CD45 
(M1/9.3.4.HL2  hybridoma,  T200), CD8  (53.6.72 hybridoma, 
Lyt2), CD4 (GK1.5 hybridoma, L3T4), Mac-1 (M1/70.15.11.5.HL 
hybridoma), and Mac-3 (M37/84,6,34 hybridoma)  (all from ATCC), 
CD3 (Boehringer, Mannheim, Germany), and anti-mouse granu- 
locyte antibody (RB6-8C5 hybridoma; Pharmingen, San Diego, 
CA). Sections were preincubated with rabbit serum and sequen- 
tiaUy  incubated with optimal dilutions of  primary antibodies, rabbit 
anti-rat IgG (Zymed Labs. Inc., San Francisco, CA) and rat peroxi- 
dase antiperoxidase  (PAP; Abbot Laboratories, North Chicago, IL). 
Each incubation step lasted 30 min and was followed  by a 10-min 
wash in Tris-buffered saline. Sections were then incubated with 
0.03% H2Oz and 0.06% 3.3' diaminobenzidine  (BDH Chemicals, 
Poole, England) for 2-5 rain, washed in tap water, and counter- 
stained with hematoxilin. The number ofimmunostained cells was 
determined by light microscopy  at 400 x  in five fields  on a 1-mm  2 
grid and is given as cells/mm  2 (mean  _+  SD). 
In Sin+ Hybridization.  The presence of cytokine mRNA was 
investigated using in situ hybridization with cDNA probes for Ib 
lc~, 1.9-kb BamHI fragment from plbl 1301, and IL-1B, 500 bp 
from plbl 130 (7), obtained from Dr. P. Lomedico (Hoffman-La 
Roche, Nutley, NJ); TNF-c~, 860-bp PstI-EcoRI fragment from 
pUC19 plasmid  containing a mouse TNF-c~ complementary  cDNA 
insert (8), courtesy of Dr. A. Cerami (The Rockefeller  University, 
New York); IFN-3,, 1.3-kb BamHI fragment from pT7/T3-19 (9), 
obtained from Dr. S. Landolfo (University of Turin, Turin, Italy); 
and 11.,4, 590-bp BamHI-ScaI  fragment contained  in plasmid  p2A-E3 
(10) (ATCC  37561). Cryostat sections  were harvested  on RNA grade 
slides, air-dried and fixed in 4% buffered paraformaldehyde  for 10 
min, dehydrated in ethanol, then sequentially rehydrated in PBS, 
50 mM MgC12, washed in 200 mM Tris-HCl-glycine, acetylated 
in 2x  SSC (lx  SSC is 0.15 M NaCI,  15 mM sodium citrate), 
0.1 M triethanolamine, 0.5% acetic anhydride (pH 8.0), washed 
in 2 x SSC, and dehydrated in ethanol. Slides were then prehybri- 
dized for 10 min at 70~  with 2x SSC, 50% formamide, and hy- 
bridized overnight at 42~  with ass-labeled specific  cDNA probe, 
1.5  x  104 cpm/section,  2x  SSC, 500/~g/ml yeast RNA,  5x 
Denhardt's solution, 10 mM dithiothreitol (DTT), and 10% dex- 
tran sulfate. Unbound and nonspecifically  bound probes were re- 
moved by sequential washes in 2x SSC, 50% formamide, and lx 
SSC, 50% formamide at 45~  and in 0.1x  SSC at room tempera- 
ture. Slides were then dehydrated in ethanol, dipped in autoradio- 
graphic emulsion NTB-2 (Eastman Kodak Company, Rochester, 
NY), and exposed for 5 d at 4~  in a light-tight box, developed 
in D19 (Eastman  Kodak Co.), fixed  in Rapid Fixer (Eastman Kodak 
Co.), and counterstained  with hematoxylin. RNA-specific  binding 
was controlled by previous digestion with 100/~g/ml ribonuclease 
A and 10 U/ml ribonuclease T  (Sigma, Poole, England). PstI- 
digested pUC9 plasmid fragments were used as negative controls. 
Cytosmears of  LPS and PHA plus ionomycin-stimulated PBL were 
inserted as positive controls in each experiment. Cells were consid- 
ered positive when the number of black grains in the cell was at 
least five times the mean number of grains present in the negative 
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on a 1-mm  2 grid and reported as cells/mm  2 (mean  -+  SD). 
Results 
Leukocyte Infiltrate Elicited by C-26/G-CSF Cell Suspensions. 
Immunocytochemistry  analysis and in situ hybridization were 
performed on cryostat sections of C-26  and C-26/G-CSF 
tumors, 24 h and 5 d after subcutaneous inoculation, to define 
the host cells involved in inhibiting the take of C-26/G-CSF 
tumor cells when injected as a tumor cell suspension. Points 
were chosen based on our previous observation that C-26-G- 
CSF cells disappeared  from the site of injection 7-10 d after 
subcutaneous inoculation into syngeneic animals (5). All cases 
examined at 24 h revealed clustered neoplastic cells surrounded 
by loose connective tissue with an evident acute neutrophilic 
inflammatory infiltrate at  the inoculation sites  (5).  After 
5 d the host reaction subsided in C-26 tumors, while a large 
number  of CD45 +/Mac-1 +/RB6-8C5 +  cells,  both  sur- 
rounding and infiltrating the neoplastic cells, were present 
in G-CSF-producing tumors (Table 1). The PMN lineage of 
the  CD45+/Mac-l+/RB6-SC5 +  cells  was  confirmed by 
morphology, and by hydrogen peroxide-nonresistant endog- 
enous  peroxidase  analysis.  A  small  percentage  of  Mac- 
1 +/Mac-3 §  macrophages,  variable  among different mice, 
was also  present but T  cells were consistently absent  (no 
staining with anti-CD3 mAb). In situ hybridization performed 
with IL-lc~, IL-1B, TNF-ot, INF-% and IL-4 cDNA probes 
5 d after tumor cell inoculation showed that 10-18% of the 
reactive  cells present in the C-26/G-CSF tumors produced 
IL-lt~, IL-lfl, and TNF-oe mRNA. (Fig.  1, a-c). The posi- 
tive cells showed the morphology of PMN and were prefer- 
entially distributed at the periphery of the tumor, frequently 
clustered around blood vessels. No hybridization with IFN-'y 
and  IL-4  probes  was  detected  (Table  1  and  Figure  1), 
confirming the absence of lymphocytes  in the cellular tumor 
infiltrate as demonstrated by immunocytochemistry. Unin- 
fected C-26 cells, which do not produce G-CSF, were virtu- 
ally without reactive infiltrate at day 5 (Table 1 and reference 
5), with rare or undetectable cytokine production (Table 1). 
C-26/G-CSF Cellular Tumor Infiltrate in Irradiated Mica  We 
have previously shown that C-26/G-CSF tumors grow in 
sublethally (600 tad) irradiated mice until blood count and 
composition normalize, resulting in tumor regression (5). 
Histological and immunocytochemical analyses  were per- 
formed on tumors during both the growing and the regres- 
sion phases to determine which cell type infiltrates the tumor 
first and which cells are present during tumor regression, 
respectively. Tumor sections obtained during the growth phase 
(days 7-20) showed a massive solid tumor without reactive 
infiltrate except  for a few large mononuclear Mac-3 + cells 
that resembled tissue macrophages (Fig.  2 a).  Reactive in- 
filtrating cells appeared  first at the periphery of the tumor 
on days 15-20 after inoculation of C-26/G-CSF cells, and 
Table  1.  Cellular Composition and Cytokine Production of Leukocytes Infiltrating C-26 or C-26/G-CSF Tumors 24 h and 5 d 
after Tumor Cell Injection 
24h  5d 
C-26  C-26/G-CSF  C-26  C-26/G-CSF 
Cell Type 
Leukocytes (CD45 §  57  _+  15" 
T lymphocytes (CD3 §  0 
Macrophages and 
granulocytes (Mac-1  §  47  _+  5 
Macrophages (Mac-3  §  9  _+  42 
Granulocytes (RB6-8C5 +)  43  _+  6 
Eosinophils  2  _+  1 
Cytokine 
IL-lt~  9  _+  1 
IL-1B  6  _+  3 
TNF-ot  3  _+  2 
IFN-3,  0 
IL-4  0 
117  _+  45  123  +  64  562  _+  87 
0  15_+8  0 
(82)$  97  _+  14  (83)  50  -+  13  (41)  500  __.  50  (89) 
(15)  10_+  6  (9)  48__  9  (39)  62_  39  (11) 
(75)  89  _+  9  (76)  13  +  10  (11)  461  _+  51  (82) 
(3)  11  +  7  (10)  8_+  5  (7)  45  _+  15  (8) 
(15)  28  _+  7  (24)  <1  67  _+  11  (12) 
(10)  12  +  3  (10)  5  _+  4  (4)  84  _+  11  (15) 
(6)  29  +  2  (24)  <1  67  _+  17  (12) 
0  0  0 
0  0  0 
The cell type was determined  by immunocytochemistry  and the presence of cytokines  by in situ hybridization  as described in Materials and Methods. 
* Mean _+ SD of cell number/mm2 tissue determined at  x 400 in a 1-mm  2 grid. 
* Positive cells were only occasionally  seen on different  sections: <1 cell/mm  z. 
S  Numbers in parentheses are ratios of positive cells to total number of CD45-infihrating leukocytes. 
153  Stoppacciaro  et al. Figure  1.  In situ hybridization  of cryostat  sections of C-26/G-CSF biopsied 5 d after tumor cell injection,  mRNA + cells were preferentially dis- 
tributed at the periphery  of the tumor where the larger infiltrate was present.  The infaltrating cells showed doughnut or segmented  nuclei typical 
of neutrophils.  (a) Ibla;  (b) 1L.lfl;  (c) TNF-ce;  (d) IFN-% Autoradiograms  were counterstained  with hematoxylin  (xl,000). 
were identified as neutrophils based on their reactivity with 
Mac-1  and RB6-8C5  mAbs  (Fig.  2,  b and c),  their mor- 
phology,  and endogenous peroxidase staining. In the next 
10 d, the inflammatory infiltrate characteristic of the regres- 
sion phase appeared. During this period, and after appear- 
ance of neutrophils, macrophages became evident, followed 
by T lymphocytes (Fig. 3). Macrophages and T lymphocytes 
increased steadily during the time of regression but most of 
Figure  2.  Kinetics  of  tumor- 
infiltrating  leukocytes in mice in- 
jected with C-26/G-CSF after 600 
tad total body irradiation. Cryostat 
se~iom were immnnosutined using 
the  peroxidase  antiperoxidase 
method. (a) Mac-3 staining;  large 
Mac-3" cells resembling tissue resi- 
dent macrophages were present in 
the tttmor as well as the surrounding 
connect'ice tissues at day 15 after in- 
jection  and before  recovery from 
radiation-induced immune suppres- 
sion  (xl,000).  (b  and  c)  C-26/ 
G-CSF  tumors stained with anti- 
PMN mAb (R.B6-8CS) from bio- 
pries performed  at days 15 and 20 
after injection, respectively,  corinth- 
stained with hematoxylin  (x250). 
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characterization  of  the  reactive 
infiltrate present in regressing C-26/ 
G-CSF tumors during the regres- 
sion phase between days 38 and 43 
after tumor injection. (a) RB6-8C5; 
(b) Mac-3; (c) eosinophils stained for 
endogenous  peroxidase; (d) CD3; 
(e) CD4; ~  CD8; counterstained 
with hematoxylin  (x 1,000). 
Table  2.  lmmunocytochemical  Characterization of Leukocytes Infiltrating C-26/C-CSF  Tumor Growing in Sublethally Irradiated  Mice 
Kinetics  of tumor  leukocyte  infiltration 
Cell  type  Early phase*  Late phase*  Rejections 
Leukocytes (CD45 §  375  •  72  u  830  •  46 
T  lymphocytes  (CD3 §  0  149  •  7  (18)  I 
T  lyrnphocytes  (CD4 +)  16  •  4  (4)  178  •  10  (21) 
T  lymphocytes  (CD8 §  0  85  •  11  (10) 
Macrophages  and 
granulocytes  (Mac-1 §  363  •  42  (96)  656  •  35  (79) 
Macrophages  (Mac-3 +)  13  •  2  (3)  234  _+  21  (28) 
Granulocytes  (RB6-8C5 +)  350  •  23  (93)  411  _+  17  (49) 
Eosinophils  24  _+  10  (6)  33  _+  16  (4) 
562  _+  67 
243  •  31 
126  _+  6 
143  _+  13 
316  _+  18 
255  _+  19 
88  •  11 
57  •  21 
(43) 
(22) 
(25) 
(56) 
(45) 
(15) 
(10) 
Tumor biopsies,  cell immunostaining,  and counting were performed  as described in Materials  and Methods. 
" 15-20 d  from irradiation  and tumor injection. 
* 25-27 d from irradiation  and tumor injection. 
S Virtual  disappearance of tumor cells from the site of tumor injection  and replacement  with granulation  tissue. 
R  Mean number of tumor-infiltrating  leukocytes/mm  2 tissue  +  SD. 
I Numbers in parentheses  are percentages  of positive  cells among total  number of infiltrating  leukocytes. 
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and probably favoring the arrival of the late-coming cells, 
were PMN (Table 2).  In fact, PMN depletion by treatment 
with the antigranulocyte mAb RB6-8C5  (Fig.  4, a  and b) 
reduced the number of both CD4 + (not shown) and CD8 + 
(Fig.  4,  c and d) T  cells within the tumor (70%  less than 
in RB6-8C5 untreated mice) and impeded tumor regression 
(see Exp. 4 in Table 5). In situ hybridization, performed to 
analyze cytokine gene expression in regressing tumors be- 
tween days 38 and 43, identified neutrophils and macrophages 
expressing IL-ltx, IL-1/3, and TNF-ct mRNA (Fig.  5, a-c), 
and cells with lymphoid morphology expressing mRNA for 
IFN-7 (Fig. 5 d). IL-4 mRNA was not detected at the tumor 
site, although IL-4 + lymphocytes were frequent in the para- 
cortical area of the draining lymph node (not  shown). 
Tumors from Irradiated Mice Treated with Anti-CD4,  -CD8, 
and -Mac-1 mAbs or Cyclosporin A  or rlFN-7.  Because the 
tumor infiltrate present during regression of C-26/G-CSF 
tumors in irradiated mice showed a different cellular compo- 
sition from that in immunocompetent animals after injec- 
tion of C-26/G-CSF  cell suspensions, we analyzed the role 
of infiltrating cells  other than neutrophils in tumor rejec- 
tion. Irradiated mice bearing C-26/G-CSF tumors were treated 
with mAbs to CD4, CDS, or Mac-l, and were immunosup- 
pressed  with  cyclosporin A  or  treated  systemically with 
rlFN-3'. Of the different treatments, those with anti-Mac-1 
and cyclosporin A  showed the most striking effect on the 
number of tumor-infiltrating cells, inducing a fourfold de- 
crease (Table 3). However, the two treatments differed in their 
effects  on  cellular  composition  and  the  role  of  tumor- 
infihrating lenkocytes. Irradiated mice treated with anti-Mac-1 
mAb showed large areas of tumor necrosis with fibrotic sub- 
stitution and presence of granulation tissue,  and with a re- 
duced number of infiltrating PMN and an increased number 
of IL-ltx (Fig.  6 a), IL-1B, and TNF-c~ mRNA-expressing 
cells  (Table  4).  Moreover,  the number of T  lymphocytes 
infiltrating the tumor remained almost unchanged, while the 
number of cells expressing IFN-3, mRNA increased (Table 
4).  In  cyclosporin A-treated  mice  tumor  regression  was 
abrogated (Table 5) and the tumors were larger. T  lympho- 
cytes were virtually absent and PMN and macrophage numbers 
were reduced three- to fourfold (Table 3). In situ hybridiza- 
tion of cyclosporin A-treated irradiated mice demonstrated 
no mRNA expression of the tested cytokines by the residual 
tumor-infiltrating cells (Table 4). Depletion of CD8 + calls 
abrogated tumor regression (Table 5) and in situ hybridiza- 
tion showed the virtual absence of mRNA for IL-ltx,  IL- 
1/3, TNF-ot, and IFN-3r (Table 4) in these tumors, suggesting 
that CD8 + T lymphocytes contribute some crucial function 
to the milieu of cytokine production by the infiltrating leu- 
kocytes. Conversely, depletion of CD4 + cells did not appear 
to affect tumor regression (Table  5).  Immunocytochemical 
Figure 4.  Immunocytochemical  characterization  of the reactive  infiltrate  present in C-26/G-CSF tumors from  mice  untreated (a and c), or treated 
(b and d), with the RB6-8C5 antigranulocytes  mAb. (a and b) Stained  with RB6-8C5 Ab; (c and d) stained with CD8 mAb. (a, c, and d)  x250; 
(b) x400 (higher  magnification  is necessary  to show the rare residual  PMN; two granulocytes  and one eosinophil  are visible); without counterstaining. 
156  Polymorphonuclear  Leukocyte-T  Cell Cooperation in Tumor Destruction Figure 5.  In situ hybridization  on cryostatic sections of C-26/G-CSF tumors during the regression phase (,,,40 d after irradiation).  (a) IL-l~x; (b) 
IL-1B; (c) TNF-~x; (d) IFN-3'. Autoradiograms  were counterstained  with hematoxylin  (xl,000). 
analysis of the CD4 antibody-treated mice showed an infiltrate 
at the tumor site similar to that of non-CD4-depleted animals 
except for the absence of CD4 + cells (Table 3). T  cell subset 
depletion  also  suggested  that  CD8 +  more  than  CD4 +  T 
lymphocytes were expressing IFN-%  Efficient depletion of 
CD4 + and CD8 + cells at the time of tumor biopsy in mice 
treated with the appropriate mAb was always confirmed by 
immunocytochemistry of spleen and lymph node sections. 
Based on the observed correlation between  the presence 
of IFN-~, transcript and the effective regression of C-26/G- 
CSF tumors, we injected rlFN-3~ into irradiated mice bearing 
these tumors;  immunohistological  analysis performed 15 d 
after treatment showed large areas of necrosis and a twofold 
increase in the number of infiltrating cells (Table 3). In situ 
hybridization revealed an increased number of cells expressing 
mRNA  for IL-lot (Fig. 6  b), IL-1/3, and TNF-ot (Table 4). 
At this time point,  tumors from mice treated with mAb to 
Mac-1 or with rlFN-3, were smaller (mean diameters,  8  x 
5 mm) than tumors from anti-CD8 or cyclosporin A  (mean 
diameters,  15  x  12 ram).  Furthermore,  injection  of mAb 
to  IFN-3,  abrogated  tumor regression  (Table 5). 
Together, the observations that tumor-infiltrating leuko- 
cytes of CD8-depleted and of cyclosporin A-treated mice ex- 
press no detectable cytokine, as well as the improved rejec- 
tion  obtained  by  rlFN-3,  treatment,  suggest  that  G-CSF 
transduced by tumor cells is not sufficient per se to induce 
rejection of an established tumor that, indeed, appears to de- 
pend  on  the presence of IFN-q'-producing  T  cells. 
Table  3.  Characterization  of C-26/G-CSF-infiltrating  Leukacytes in Sublethally Irradiated Mice Treated with mAbs 
to C1M,  CD8,  and Mac-1 or with rlFN-3' or Cyclosporin A 
Treatment 
Cell type  None  CD4  CD8  Mac-1  IFN-'y  cy A 
CD45 +  1,006  _+  46*  956  _+  253  536  _+  59  253  +  11  2,326  _+  149  239  _+  41 
CD3 §  200  _+  21  (20)s  86  _+  9  (9)  112  +_  15  (21)  154  +  13  (61)  581  _+  45  (25)  2  +  2  (1) 
CD4 §  181  _+  13  (18)  0  150  _+  21  (28)  144  _+  12  (57)  488  +  66  (21)  5  +  3  (2) 
CD8 §  40  _+  7  (4)  105  +  17  (11)  0  23  _+  7  (9)  209  _+  23  (9)  2  _+  2  (1) 
Mac-1 +  814  +  97  (81)  871  _+  11  (91)  402  _+  51  (75)  83  _+  7  (33)  1,860  _+  93  (80)  222  +_  11  (93) 
Mac-3 §  332  _+  10  (33)  413  +_  19  (43)  353  +_  13  (66)  53  +  5  (21)  767  +_  14  (33)  100  _+  9  (42) 
RB6-8C5 §  462  _+  11  (46)  479  _+  15  (50)  32  _+  6  (6)  28  _+  8  (11)  1,046  +_  35  (45)  117  _  9  (49) 
Eosinophils  8  _+  4  (1)  8  -+  2  (1)  10  _+  3  (2)  0  48  _+  9  (2)  12  +  3  (5) 
Treatments were as described in Materials and Methods; tumor biopsies were obtained between days 38 and 43 after irradiation and tumor injection. 
Frozen sections were stained with mAb by immunocytochemistry (peroxidase antiperoxidase method). 
* Mean number of cells/mm  2 _+  SD positive for immunostaining. 
* Numbers in parentheses are percentages of positive cells among total number of infiltrating leukocytes, 
157  Stoppacciaro  et al. Figure  6.  Effects of anti-Mac-1 mAb (a), rlFN-3~ (b), or anti-CD8 mAb (c), on IL-lcr mRNA expression.  In situ hybridization indicates a significant 
increase in cells expressing IL-lc~ mRNA (compare with Fig.  4 a for untreated control) in C-26/G-CSF tumors from mice treated with anti-Mac-1 
mAb or rlFN-% 
Discussion 
Tumor cells genetically engineered to produce cytokines 
stimulate host cell immunity in syngeneic mice, eventually 
resulting in complete tumor growth inhibition.  In  some 
studies, the immune cells involved were characterized by im- 
munohistology  of tissue at the site of tumor injection (11-16) 
or by FACS  |  analysis of isolated infiltrating cells (17) whose 
functional activity was evaluated by depleting the mice with 
relevant  mAb.  The emerging picture is that of a complex 
interaction among cells involved in nonspecific (granulocytes 
and macrophages) and specific (T ceUs) immune responses 
(reviewed  in reference  2).  Both cell-cell contacts and flow 
of cytokines, produced by the infiltrating leukocytes, should 
influence these interactions.  In this paper we provide evidence 
identifying the cell types that infiltrate the tumor and the 
cytokine that these cells express in situ. Two experimental 
models were used. One enabled analysis of the inhibition of 
tumor take after injection of C-26 cells engineered to pro- 
duce G-CSF.  The second allowed study of the mechanisms 
of tumor rejection since C-26/G-CSF cells were previously 
found to form large tumors when injected into sublethally 
Table  4.  Effects  of Anti-CD4,  -CD8,  and -Mac-1 mAbs or rlFN-'7  or Cyclosporin A  Treatments on  Cytokine  mRNA  Expression by 
C-26/G-CSF-infiltrating  Leukocytes in Sublethally Irradiated Mice 
No.  of cells expressing mRNA/mm  2 in tumors  from mice treated with: 
Cytokine  None  CD4  CD8  Mac-1  rlFN-3~  cy A 
IL-la  5  +_  2  2  _+  2  (1  26  +_  9  10  +_  2  <1 
IL-1/~  3  _+  1  12  _+  3  <1  21  _+  3  36  _+  7  -* 
TNF-ot  4  _+  3  4  _+  4  <1  25  +  8  27  _+  10  - 
IFN-3,  9  _+  2  1 _+  2  -  13  _+  4  2  _+  2  - 
IL-4  -  -  ND  -  - 
mRNA content was detected by in situ hybridization on cryostat sections using 3sS-labeled cDNA probes and revealed by autoradiography. Positive 
cells/mm  2 were counted at  x 400 in a  1-mm  2 grid. 
* Not detectable. 
158  Polymorphonuclear Leukocyte-T  Cell Cooperation in Tumor Destruction Table  5.  Effect of Leukocyte Subpopulation Depletion, Immunosuppression with Cyclosporin A, or Treatment with rlFN-'y 
No. of mice with progressing  tumor/no, of mice observed 
Treatment  Exp.  1  Exp.  2  Exp.  3  Exp.  4 
None 
Anti-CD4 plus -CD8 
Anti-CD4 
Anti-CD8 
Anti-Mac-1 
Anti-IFN-? 
Anti-PMN 
Cyclosporin A 
rIFN-y 
0/7*  4/11  1/6 
5/6 
2/9  0/6 
7/9  6/7 
0/2  0/1 
6/6 
1/7 
5/5 
6/6 
4/4 
0/3  0/5 
" Number of mice with tumor, or mice that died because of tumor, after irradiation  and C-26/G-CSF cell injection/number  of mice observed  (ran- 
domly chosen from mice treated for immunohistology  and in situ hybridization  but not killed). In each experiment, mice came  from the same pool 
of irradiated and treated mice. 
irradiated mice and then to regress when mice reconstituted 
leukocyte function. 
Our data confirm that neutrophils represent the majority 
of the reactive cells involved in C-26/G-CSF tumor inhibi- 
tion (5). In fact, our previous study demonstrated that when 
C-26 and C-26/G-CSF cells were mixed together before in- 
jection, only C-26/G-CSF cells were eliminated, and PMN 
were detected at the site of injection until C-26/G-CSF cells 
were present (18). We now show that the neutrophils present 
at the site of tumor cell injection express transcripts for IL- 
lol, IL-1B, and TNF-cr, cytokines that might be part of the 
granulocyte weapon for tumor destruction and not simply 
reflective of their activated state. Furthermore, PMN that pro- 
duce cytokines appear to have a pivotal role in the regression 
of C-26/G-CSF tumors established in sublethally irradiated 
mice. PMN were clearly the first cells to infiltrate the tumor 
during leukocyte self-reconstitution. Possibly, the G-CSF pro- 
duced by large tumors determines the persistence of PMN, 
and the production of IL-1 and TNF-ol by PMN activates 
vascular endothelial cells, favoring the migration of macro- 
phages and T  cells to the tumor site (reviewed in reference 
19). However, only a fraction of infiltrating PMN were found 
to express IL-1 and TNF,  consistent with the observation 
in vitro that PMN express IL-I~ mKNA quickly and very 
briefly when stimulated (20), probably because of their short 
life span.  On the other hand,  the preferential distribution 
of positive cells at the periphery of the tumor and around 
the blood vessels raises the possibility that cytokine production 
occurs in newly arrived, young PMN. Note that treatment 
with  antibodies  to Mac-1  reduced the number of tumor- 
infiltrating PMN but increased the number of PMN that 
expressed IL-1  and TNF-a,  suggesting the presence of a 
Mac-1 + cell population with suppressive  effects (21). 
Granulocytes,  which  are  usually considered  terminally 
differentiated cells active only during inflammation, have been 
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found to exert antitumoral activity in vivo (5, 22-24). Their 
ability to synthesize and release cytokines upgrades their role 
as coregulators of the immune response (25) through antigen 
presentation ability (26, 27). PMN that express IL-1/3, IL-lot 
(28-30),  and TNF-ot mRNA (31,  32) also synthesize and 
secrete the proteins when stimulated (28-31).  CSFs,  IL-3, 
IL-8, TGF-cz, and TGF-3 were found to be expressed by ei- 
ther neutrophilic or eosinophilic PMN (review in reference 
25).  Similarly, it was IL-6 that is known to stimulate cell 
proliferation and cytotoxic function in T lymphocytes (33). 
Analysis of the antitumor response has provided evidence of 
PMN-T lymphocyte  cooperation. Depletion of PMN by mAb 
treatment, in rats, resulted in abrogation of specific trans- 
plantation resistance to challenge with syngeneic, chemically 
induced tumors used for immunization (24).  Tumors en- 
gineered to produce IL-4 or IL-2 are first infiltrated with PMN 
and subsequently with T lymphocytes (12, 34). This sequen- 
tial infiltration of different leukocyte types is characteristic 
of many acute inflammatory processes,  suggesting the exis- 
tence of a general mechanism governing leukocyte traf~c that 
largely involves IL-lol and TNP-ot (35). Nevertheless, PMN 
plays a central role in tumor rejection of both IL-4- (36) and 
in G-CSF- (this paper) producing tumors. Our data also sug- 
gest a reverse direction of PMN-T lymphocyte cooperation, 
wherein depletion  of CD8 + cells  reduces the number of 
infiltrating PMN, thus preventing tumor regression. Expres- 
sion of IFN-3' mKNA by CD8 + cells infiltrating regressing 
tumors suggests some role for IFN-'y in sustaining PMN sur- 
vival and function (37).  In fact, we find that antibodies to 
IFN-? abrogate tumor regression. T cell expression of IFN-~ 
mKNA may well be induced unspecifically by PMN- and 
monocyte-released IL-1 and TNF,  as occurs after infection 
with microbial pathogen (38). Noncytotoxic CD8 + tumor- 
infiltrating lymphocytes have been reported to eradicate lung 
tumors in irradiated mice through the release of TNF and IFN-3, (39). Thus, IFN-3' along with IL-1 and TNF-ol ap- 
pear to provide a favorable setting for tumor destruction, a 
notion consistent  with  our observation in  tumors  of cy- 
dosporin A-treated mice where the remaining leukocytes were 
negative for cytokine mRNA expression and tumors did not 
regress. Thus, G-CSF production by neoplastic cells is not 
sufficient per se to induce regression of an established tumor, 
whereas it can inhibit tumor take. 
Together, our data demonstrated the occurrence of events 
expected when the appropriate combination of cytokines is 
released at the tumor site.  Such a combination might well 
be initially triggered by a single cytokine, as in our G-CSF 
model. 
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